← Back to Search

Behavioral Intervention

Mobile Therapy for Depression

N/A

Waitlist Available

Led By Jennifer Dahne, PhD

Research Sponsored by Medical University of South Carolina

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18+

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up between baseline and week 12

Awards & highlights

Study Summary

This trial is testing whether a mobile app can help treat depression. Participants will be randomly assigned to either use the app or not, and will be asked to complete electronic questionnaires throughout the study period.

Who is the study for?

This trial is for adults over 18 with depression, as indicated by a score of >10 on the PHQ-9. Participants must be willing to use a mobile app for treatment, own a smartphone compatible with iOS or Android, have an email they check daily or access to text messages, and be enrolled in Epic's MyChart program. Those with current suicidal thoughts are excluded.Check my eligibility

What is being tested?

The study evaluates 'Moodivate', a mobile app designed for treating depression. Over 12 weeks, participants will either receive the app and use it daily or continue their usual care without the app. Their progress will be monitored through electronic questionnaires.See study design

What are the potential side effects?

Since this trial involves using a mobile therapy application rather than medication, traditional side effects are not expected; however, users may experience discomfort if personal issues arise during use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ between baseline and week 12

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~between baseline and week 12

This trial's timeline: 3 weeks for screening, Varies for treatment, and between baseline and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Mean Score of Depressive Symptoms

Trial Design

3Treatment groups

Experimental Treatment

Group I: Group C- Moodivate + EHRExperimental Treatment1 Intervention

Participants randomized to the Moodivate + EHR condition will receive similar instructions as those randomized to Moodivate, but will also be instructed that their PCP will have access to metrics related to their app utilization and may choose to follow-up with them regarding treatment utilization and response. The PCP for each participant randomized to this condition will be provided EHR access to Moodivate metrics which will include metrics related to change in mood, frequency of app utilization, and frequency of activity completion. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Group II: Group B- MoodivateExperimental Treatment1 Intervention

Participants randomized to the Moodivate condition will be instructed to utilize Moodivate regularly, at least once per day, for the treatment of depressed mood. Participants in the Moodivate group will receive a download code to download the Moodivate mobile application. Moodivate is a mobile app for individuals with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, and rate mood daily. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Group III: Group A- Treatment as UsualExperimental Treatment1 Intervention

Participants in the treatment as usual group will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Treatment as Usual

2016

Completed Phase 3

~2710

Behavioral Activation Therapy app

2021

N/A

~110

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor

932 Previous Clinical Trials

7,393,740 Total Patients Enrolled

40 Trials studying Depression

6,303 Patients Enrolled for Depression

National Institutes of Health (NIH)NIH

2,696 Previous Clinical Trials

6,951,889 Total Patients Enrolled

53 Trials studying Depression

46,378 Patients Enrolled for Depression

Jennifer Dahne, PhDPrincipal InvestigatorMedical University of South Carolina

3 Previous Clinical Trials

285 Total Patients Enrolled

3 Trials studying Depression

285 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants currently being welcomed into this research endeavor?

"According to the clinicaltrials.gov listings, this trial has ceased recruitment of participants despite initial posting on December 10th 2021 and its most recent update occuring February 8th 2022. However, there are 1135 other medical studies currently recruiting candidates for active participation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of a Mobile Therapy for Elevated Depressive Symptoms

Jennifer Dahne 2021. "Evaluation of a Mobile Therapy for Elevated Depressive Symptoms". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04463914.

All > Depression > Treatment Resistant Depression